AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study

AstraZeneca Plc's immunotherapy Imfinzi did not meet the main goals of a late-stage study testing the drug as a treatment for advanced head and neck cancer, the London-listed drugmaker said on Friday.